 "AstraZeneca Covid-19 vaccine, AstraZeneca")
AstraZeneca on Thursday struck a deal with the firm behind Imperial College London's experimental Covid-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas.
Under the deal, VaxEquity, a start-up founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are met, in addition to royalties on approved drugs and equity investment from AstraZeneca.
Disclaimer: No Business Standard Journalist was involved in creation of this content
